Evaluation of Bioavailability of Diclofenac Dermal Products

NCT03145259 | Completed Early Phase 1 Results FDA Drug

• 1 other identifier: HP-00067047
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations.

Conditions

Bioavailability

Outcome Measures

Primary Outcomes (1)

• Serum Diclofenac Concentrations

  Study Session 1: within 60 min prior to dosing, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 24, 27, 30, 32, 51 h Study Session 2: within 60 min prior to dosing, 1, 2, 3, 4, 5, 6, 7, 23, 26, 29, 31, 47 h Study Session 3: no blood samples obtained

  blood samples obtained over 51 hour time period for study session 1 and over 47 hour time period for study session 2; through study completion

Study Arms (3)

Diclofenac patch

OTHER

Study Session 1: diclofenac epolamine patches (PK) \[51 h study duration\]

Drug: Diclofenac Epolamine Patch

Diclofenac solution

OTHER

Study Session 2: diclofenac sodium solution (PK) \[47 h study duration\]

Drug: diclofenac sodium solution

Diclofenac patch and solution

OTHER

Study Session 3: diclofenac epolamine patch pieces and diclofenac sodium solution (no PK, for skin tape stripping) \[51 h study duration\]

Drug: Diclofenac Epolamine Patch; Drug: diclofenac sodium solution

Interventions

Diclofenac Epolamine Patch DRUG

patch

Also known as: patch

Diclofenac patch; Diclofenac patch and solution

diclofenac sodium solution DRUG

solution

Also known as: solution

Diclofenac patch and solution; Diclofenac solution

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Men or non-pregnant, women who are of any ethnic background between the age of 18 to 45 years old
• Subjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco, snuff, gum, patches or electronic cigarettes) over the previous 2 months and are not currently using tobacco products
• Provide written informed consent before initiation of any of the study procedures
• Agree not to participate in another clinical trial/study during the study period or to participate in an investigational drug study for at least 1 month after the last study session
• Able to adhere to the study protocol and study restrictions
• Able to participate in all study sessions
• Has a volar forearm of either at least 24 cm (9.45 inches) in length or of sufficient size that can accommodate the products to be tested in a study area that begins at least 5 cm (1.97 inches) above the wrist and ends a minimum of 0.5 cm (0.197 inches) below the antecubital fossa (i.e., the bend in the arm at the elbow).
• Subjects have upper arms large enough to allow for placement of two 140 cm2 \[21.7 in2\] patches (distance from acromion process of the scapula to olecranon process should be a minimum of 35 cm \[13.8 inches\]; circumference of upper arms should be a minimum of 28 cm \[11.02 inches\] and 200 cm2 \[31 in2\] area for application of solution
• Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history
• Negative urine drug screening test (cannabinoids, amphetamines, barbiturates, benzodiazepine, cocaine, methadone, opiates, PCP)
• Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT) and aspartate aminotransferase (AST)
• Have normal screening laboratories for urine protein and urine glucose
• Female subjects must be of non-childbearing potential (as defined as surgically sterile \[i.e. history of hysterectomy or tubal ligation\] or postmenopausal for more than 1 year), or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner
• Agrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study session
• Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)

You may not qualify if:

• Women who are pregnant, lactating, breast feeding or have a positive serum pregnancy test at enrollment or positive urine pregnancy test on the morning of the first day of each study session
• Smokers (current use or use over the previous 2 months of nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco, snuff, gum, patch or electronic cigarettes)
• Participation in any ongoing investigational drug trial/study or clinical drug trial/study
• History as either reported by the subject or evident to the Medically Accountable Investigator (MAI) of infectious disease or skin infection or of chronic skin disease (e.g., psoriasis, atopic dermatitis)
• History of diabetes
• History of significant skin cancers (e.g., melanoma, squamous cell carcinoma) except basal cell carcinomas that were superficial and did not involve the investigative sites
• Body Mass Index (BMI) ≥30 kg/m2
• History of chronic obstructive pulmonary disease or cor pulmonale, or substantially decreased respiratory reserve, hypoxia, hypercapnia or pre-existing respiratory depression
• Active positive Hepatitis B, C and/or HIV serologies
• Positive urine drug screening test
• Use of chronic prescription medications during the period 0 to 30 days; or over-the-counter medication (e.g. antihistamines, topical corticosteroids) and short term (\<30 days) prescription medications during the period 0-3 days before a study session (vitamins, herbal supplements and birth control medications not included)
• Currently taking daily oral nonsteroidal anti-inflammatory drug \[NSAIDs\] (aspirin, ibuprofen, naproxen, etc…)
• Currently taking daily anticoagulants or within the past month prior to entry into the study (warfarin, heparin, rivaroxaban, dabigatran, etc…), ACE-inhibitors, cyclosporine, diuretics, lithium or methotrexate
• Donation or loss of greater than one pint of blood within 60 days of entry to the study
• Any prior adverse reaction or hypersensitivity to diclofenac, aspirin, ibuprofen, naproxen or other nonsteroidal anti-inflammatory drug (NSAID), other inactive ingredients in the patch or topical solution or to adhesives or tapes used to cover or tape strip the treatment sites

Sponsors & Collaborators

• University of Maryland, Baltimore: lead
• Food and Drug Administration (FDA): collaborator

Study Sites (1)

General Clinical Research Center (GCRC) at the University of Maryland Medical Center

Baltimore, Maryland, 21201, United States

Location

MeSH Terms

Interventions

Transdermal Patch; Solutions

Intervention Hierarchy (Ancestors)

Equipment and Supplies; Pharmaceutical Preparations

Results Point of Contact

• Title: Dr. Audra Stinchcomb
• Organization: University of Maryland, Baltimore School of Pharmacy

astinchc@rx.umaryland.edu

410-706-2646

Study Officials

• Audra L Stinchcomb, PhD

  University of Maryland Baltimore School of Pharmacy

  PRINCIPAL INVESTIGATOR

• Hazem E Hassan, PhD

  University of Maryland Baltimore School of Pharmacy

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: The same 12 volunteers received all treatments in three separate study arms.

Study Record Dates

• First Submitted: May 1, 2017
• First Posted: May 9, 2017
• Study Start: April 19, 2017
• Primary Completion: August 29, 2019
• Study Completion: May 15, 2020
• Last Updated: June 30, 2020
• Results First Posted: June 16, 2020

Record last verified: 2020-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)